Valeant has been touting the potential of psoriasis candidate brodalumab to help the struggling company stage its turnaround. But ahead of an advisory…

Drugs companies continue to raise their prices.

In the second straight resounding vote in favor of a biosimilar in as many days, Sandoz’s version of Amgen’s Enbrel earned unanimous support from an FDA panel…

Already the world’s best-selling vaccine, Pfizer’s Prevnar 13 got yet another boost Tuesday with an expanded FDA approval in adults aged 18 to 49.

Amgen is spending Tuesday making its case for a biosimilar approval before an FDA advisory committee. But come Wednesday, it’ll be Novartis’ Sandoz doing the…

Shire has the approval it’s been waiting for--and the label it wanted, too.

Gilead cancer drug Zydelig--flagged earlier this year after serious adverse events cropped up in studies--can stay on the market with some new recommendations…

Novartis’s Sandoz is aiming to bring a biosimilar of Amgen anti-TNF giant, Enbrel, to market. And it just rolled out efficacy data that could help it get there.

Will pharma’s Brexit fears come to pass? The U.K.’s life sciences minister, George Freeman, isn't ruling out the idea of splitting Britain’s drug…